VIDLARECO: C-MAC Videolaryngoscope for Insertion of a Transesophageal Echocardiography Probe in ICU Patients

Sponsor
Hospital Clinico Universitario de Santiago (Other)
Overall Status
Recruiting
CT.gov ID
NCT04980976
Collaborator
(none)
100
1
2
13
7.7

Study Details

Study Description

Brief Summary

Transesophageal echocardiography (TEE) is commonly used in operating room (cardiac surgery), as well as in other critical care settings. A recent meta-analysis including only three randomized studies demonstrated that the use of a videolaryngoscope for transesophageal echocardiography probe insertion in anesthetized patients undergoing open cardiac surgery was associated with a significant reduction in the number of attempts. insertion and complications rate, compared with blind insertion or a laryngoscope-assisted insertion.

ICU patients are usually intubated, with multiple complications, requiring high doses of catecholamines, and with frequent coagulation disorders. Many of these patients, during their stay in the ICU, require a transesophageal echocardiogram. On multiple occasions, due to the critical situation of the patients, due to edema, and coagulation alteration, the placement of the echocardiography probe can be difficult, leading to complications, such as gastric bleeding or lesions in the oropharyngeal mucosa.

To avoid complications during the insertion of the TEE tube, the investigators consider it necessary to introduce it in the fewest possible attempts.

The primary aim of the present study was to compare the success rate of TEE probe insertion at the first attempt betweenn the C-MAC videolaryngoscope assisted insertion and the blind insertion technique.

The secondary aim was to compared differences between the 2 groups in the incidence of complications ( oropharyngeal mucosal injury, hematoma, ….), overall success rate, the number of insertion attempts, and the duration of insertions.

Condition or Disease Intervention/Treatment Phase
  • Device: Blind insertion technique
  • Device: C-MAC videolaryngoscope insertion technique
N/A

Detailed Description

One hundred intubated ICU adult patients that require transesophageal echocardiography insertion, will be randomized by means of a computer-generated randomization order into two groups: Conventional group (Group Blind), and videolaryngoscope group (group C-MAC).

Success rate of the selected technique (first attempt), overall success rate, number of attempts, complications, and duration of insertion for technique will be noted.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
After TEE insertion, the pharyngeal mucosa will be evaluated with de C-MAC videolaryngoscope by an anesthesiologist who were blinded to the study
Primary Purpose:
Prevention
Official Title:
C-MAC Videolaryngoscope for Insertion of a Transesophageal Echocardiography Probe in ICU Patients. A Randomized Controlled Trial
Actual Study Start Date :
Jul 19, 2021
Anticipated Primary Completion Date :
Jul 19, 2022
Anticipated Study Completion Date :
Aug 19, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Conventional blind insertion technique.

Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.

Device: Blind insertion technique
Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.

Experimental: C-MAC videolaryngoscope insertion technique

Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique to advance into esophagus under direct vision.

Device: C-MAC videolaryngoscope insertion technique
Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique

Outcome Measures

Primary Outcome Measures

  1. Difference in the first attempt success rate (percentage) [Participants will be followed from the beginning of the transesophageal echocardiography probe insertion through the mouth to the confirmation of successful insertion (10 minutes or three attempts)]

    To compare the difference in the first attempt (percentage) of different techniques for insertion of transesophageal echocardiography probe.

Secondary Outcome Measures

  1. Difference in the overall success rate (percentage) [Participants will be followed from the beginning of the transesophageal echocardiography probe insertion through the mouth to the confirmation of successful insertion (10 minutes or three attempts)]

    To compare the difference overall success rate (percentage) of different techniques for insertion of transesophageal echocardiography probe.

  2. Difference in the incidence of complications (percentage) [Participants will be followed from the beginning of the transesophageal echocardiography probe insertion through the mouth to the confirmation of successful insertion (10 minutes or three attempts) and in the next 24 hours.]

    To compare the difference in complications of different techniques for insertion of transesophageal echocardiography probe.

  3. Difference in the duration of insertion [Participants will be followed from the beginning of the transesophageal echocardiography probe insertion through the mouth to the confirmation of successful insertion (10 minutes or three attempts) and in the next 24 hour and in the next 24 hours.]

    To compare the duration of different techniques for insertion of intransesophageal echocardiography probe.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ICU intubated patients that require transesophageal echocardiography probe insertion
Exclusion Criteria:
  • patients younger than 18 years and older than 85 years

  • oropharengeal infection

  • esophageal injury and anatomic abnormalities

  • Consent refusal for participating in the trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Manuel Taboada Santiago de Compostela La Coruña Spain 15701

Sponsors and Collaborators

  • Hospital Clinico Universitario de Santiago

Investigators

  • Principal Investigator: Manuel Taboada, University Clinical Hospital of Santiago de Compostela

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Manuel Taboada Muñiz, Clinical Professor, Hospital Clinico Universitario de Santiago
ClinicalTrials.gov Identifier:
NCT04980976
Other Study ID Numbers:
  • CEIG 2020/375
First Posted:
Jul 28, 2021
Last Update Posted:
Mar 8, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Manuel Taboada Muñiz, Clinical Professor, Hospital Clinico Universitario de Santiago
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2022